Comparative Pharmacology
Head-to-head clinical analysis: ENBREL versus SIMPONI ARIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBREL versus SIMPONI ARIA.
ENBREL vs SIMPONI ARIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Golimumab is a human IgG1κ monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), preventing its interaction with p55 and p75 cell surface TNF receptors. This reduces pro-inflammatory cytokine production and immune cell activation.
50 mg subcutaneous injection once weekly
2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.
None Documented
None Documented
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Terminal elimination half-life approximately 10-13 days (mean 12 days), allowing for every 2-week dosing after initial loading regimen.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; negligible renal (0.1%) and fecal (<1%) excretion; no significant biliary elimination.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor